Preparing market rhythm analysis...
News Center
Browse cached source articles used by the rhythm engine. Filter by ticker, sentiment, or keyword, then open the stock rhythm page for deeper daily, swing, and long-term analysis.
Cached Articles
35963
Tickers With News
516
Showing Now
50
Top Ticker
AAPL
Featured Tickers
Jump straight into the most important tickers for testing and market coverage.
Latest Articles
Bernstein analyst Eve Burstein maintains Agilent Technologies (NYSE:A) with a Outperform and raises the price target from $155 to $180.
Stifel analyst Daniel Arias maintains Agilent Technologies (NYSE:A) with a Buy and raises the price target from $170 to $180.
RBC Capital analyst Dan Leonard maintains Agilent Technologies (NYSE:A) with a Outperform and raises the price target from $155 to $185.
Agilent (A) stock is upgraded to Buy after strong Q3 2026 results; see revenue/EPS growth, margin gains, FY26 outlook, and valuation discount. See more here.
Evercore ISI Group analyst Vijay Kumar maintains Agilent Technologies (NYSE:A) with a Outperform and raises the price target from $148 to $172.
Citigroup analyst Patrick Donnelly maintains Agilent Technologies (NYSE:A) with a Buy and raises the price target from $185 to $190.
TD Cowen analyst Dan Brennan maintains Agilent Technologies (NYSE:A) with a Buy and raises the price target from $155 to $180.
2026-08-27. The following slide deck was published by Agilent Technologies, Inc.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
JP Morgan analyst Casey Woodring maintains Agilent Technologies (NYSE:A) with a Overweight and raises the price target from $180 to $190.
Lithium prices rebound as CATL shutdown risks a deficit; miners post strong H1 results, and new supply deals form. Read the full news roundup here.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.
Agilent Technologies (NYSE:A) reported quarterly earnings of $1.62 per share which beat the analyst consensus estimate of $1.49 by 8.72 percent. This is a 18.25 percent increase over earnings of $1.37 per share from the
Agilent Technologies (NYSE:A) raises FY2026 Adj EPS guidance from $6.00-$6.10 to $6.18-$6.21 vs $6.06 analyst estimate. Raises FY2026 sales outlook from $7.390 billion-$7.490 billion to $7.490 billion-$7.510 billion vs
Agilent Technologies (NYSE:A) released third-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial
Agilent Technologies, Inc. (A) Q3 2026 Earnings Call August 26, 2026 4:30 PM EDTCompany ParticipantsTejas Savant - Vice President of Investor...
These are the stocks posting the largest moves in after-hour trading.
Agilent Technologies (NYSE:A) is looking for Q4 Adj EPS of $1.71-$1.74 vs $1.72 analyst estimate. sees sales of $1.980 billion-$2.000 billion vs $1.971 billion analyst estimate.
Broadcom Inc.: AI chip growth targets, SPV financing and default risks, insider selling, and valuationâsee why investors may avoid now. Click for more on AVGO stock.
Agilent Technologies has a company-confirmed earnings report dropping after the close on August 26, and every operating lever heading into that date is pointing the same direction. Here is what retirement-focused investors need to understand before the bell rings.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Agilent (A), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended July 2026.
Despite Agilent Technologies’ strong performance relative to the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.
Here is how Adicet Bio, Inc. (ACET) and Agilent Technologies (A) have performed compared to their sector so far this year.
Dublin, Aug. 18, 2026 (GLOBE NEWSWIRE) -- The "Cannabis Testing Services - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering. The global cannabis testing services market was valued at USD 359.68 million in 2025 and is expected to increase from USD 397.85 million in 2026 to USD 688.46 million by 2031. The market is projected to register a compound annual growth rate of 11.59% during the 2026-2031 forecast period.
MDT vs. A: Which Stock Is the Better Value Option?
Thermo Fisher Scientific: Biopharma Recovery And Share Gains Support The Upside
Danaher: 2027 Growth Reacceleration Should Drive Upside
Morgan Stanley analyst Kallum Titchmarsh maintains Agilent Technologies (NYSE:A) with a Overweight and raises the price target from $160 to $175.
Agilent Technologies (NYSE:A) secured expanded European approval for its PD-L1 IHC 22C3 pharmDx test for ovarian cancer applications. The CE-marked indication now covers patients with ovarian, fallopian tube, and primary peritoneal carcinoma in the EU. The move strengthens Agilent's oncology diagnostics portfolio and supports wider use of targeted cancer therapies in Europe. For readers looking to explore more stocks tied to the rise of data driven tools in cancer care and diagnostics, a...
BioLife Solutions (BLFS) delivered earnings and revenue surprises of +500.00% and +1.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global gRNA Market size & share revenue was valued at approximately USD 518 Million in 2024 and is expected to reach USD 616 Million in 2025 and is expected to reach around USD 2950 Million by 2034, at a CAGR of 19% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Thermo Fisher Scientific Inc., Agilent Technolo
Investors need to pay close attention to A stock based on the movements in the options market lately.
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Envista (NVST) delivered earnings and revenue surprises of +24.24% and +2.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Kestra Medical Technologies, Ltd. (KMTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
XRAY's Q2 results are likely to reflect transformation investments, dealer inventory cuts and weak implants, while Wellspect growth offers support.
COR's Q3 results could reflect specialty pharma strength, oncology expansion and margin gains, even as pricing dynamics and GLP-1 trends pressure revenues.
SOLV's Q2 results are likely to benefit from segment strength, Acera gains and cost savings, offset by tariffs and ERP-related sales timing shifts.
TMO lifted its 2026 outlook after Q2 topped estimates, driven by stronger demand, acquisitions and margin gains. Can the momentum continue?
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Agilent Technologies Inc. (NYSE:A) just extended its diagnostics franchise into one of oncology’s toughest corners. On July 23, the company said European regulators had certified its PD-L1 IHC 22C3 pharmDx test, Code SK006, as a companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma. That lets pathologists flag patients who might benefit from […]
TMO is expanding bioproduction, AI tools and clinical data capabilities, but execution will be key as competition intensifies.
RVTY heads into Q2 earnings with improving Life Sciences demand and resilient Diagnostics. Can stronger margins offset lingering headwinds?
Stryker (SYK) delivered earnings and revenue surprises of +6.65% and +0.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Organic revenue still fell, yet a segment returning to growth and a raised outlook were enough to reprice the stock in a single session.
SANTA CLARA, Calif., July 29, 2026--Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on behalf of Professor Zongwei Cai. The award recognizes Professor Cai's innovative research focused on developing advanced analytical approaches for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, a growing area of importance for environmental and public health research
Here is how argenex SE (ARGX) and Agilent Technologies (A) have performed compared to their sector so far this year.
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Precision Diagnostics And Medicine Market size & share revenue was valued at approximately USD 147.23 Billion in 2025 and is expected to reach USD 159.66 Billion in 2026 and is expected to reach around USD 345.75 Billion by 2035, at a CAGR of 8.91% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are F. Hoff
SANTA CLARA, Calif., July 28, 2026--Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day.
DXCM's Q2 results may reflect strong G7 15 Day adoption, broader reimbursement, and expanding CGM demand as investors watch for continued double-digit revenue growth.
